An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis
Status:
Completed
Trial end date:
2020-11-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the long-term safety and any side effects of
baricitinib in participants who have completed a previous baricitinib rheumatoid arthritis
study.
The study provides for 7 years of additional treatment with baricitinib.